Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Vitamin D is a New Promising Inhibitor to the Main Protease (Mpro) of COVID-19 by Molecular Docking

Al-Mazaideh et al., Journal of Pharmaceutical Research International, doi:10.9734/jpri/2021/v33i29B31603
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
In Silico study showing vitamin D binding with Mpro of SARS-CoV-2. Among the compounds tested, vitamin D had the highest potential interaction in terms of total H-bond, van der Waal, torsional, and desolvation energy. Authors recommend adding vitamin D to COVID-19 treatment protocols.
21 preclinical studies support the efficacy of vitamin D for COVID-19:
Vitamin D has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function20-23. Vitamin D inhibits SARS-CoV-2 replication in vitro10,17, mitigates lung inflammation, damage, and lethality in mice with an MHV-3 model for β-CoV respiratory infections10,17, reduces SARS-CoV-2 replication in nasal epithelial cells via increased type I interferon expression13, downregulates proinflammatory cytokines IL-1β and TNF-α in SARS-CoV-2 spike protein-stimulated cells9, attenuates nucleocapsid protein-induced hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway14, may be neuroprotective by protecting the blood-brain barrier, reducing neuroinflammation, and via immunomodulatory effects24, minimizes platelet aggregation mediated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling8, and improves regulatory immune cell levels and control of proinflammatory cytokines in severe COVID-1925. Symptomatic COVID-19 is associated with a lower frequency of natural killer (NK) cells and vitamin D has been shown to improve NK cell activity26,27.
Al-Mazaideh et al., 26 May 2021, peer-reviewed, 4 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperVitamin DAll
Vitamin D is a New Promising Inhibitor to the Main Protease (Mpro) of COVID-19 by Molecular Docking
Ghassab M Al-Mazaideh, Mohammed H Shalayel, Farhan K Al-Swailmi, Saleem H Aladaileh
Journal of Pharmaceutical Research International, doi:10.9734/jpri/2021/v33i29b31603
In this study, vitamin D has shown greater efficacy of binding with M pro of COVID-19 compared to the recently recommended drugs. The docking study was simulated to streamline interaction effects of Vitamin D, Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and Azithromycin complexes with the active site of M pro . Vitamin D is found to have the highest potential interaction in terms of total H-bond, van der Waal, torsional, and desolvation energy which were the lowest among all the selected drugs. The hydroxyl group of vitamin D and the thiol group of M pro cysteine had played a leading role in increasing Vitamin D binding and stability with the M pro pocket by contribution to the inception of three hydrogen bonds. The study recommend that vitamin D can be added to the COVID-19 treatment protocol, which may have the desired effect on viral replication inhibition and decreases mortality.
CONSENT It's not applicable. ETHICAL APPROVAL It's not applicable. COMPETING INTERESTS Authors have declared that no competing interests exist.
References
Baez-Santos, John, Mesecar, The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds, Antivir. Res
Bikle, Vitamin D metabolism, mechanism of action and clinical applications, Chem. Biol, doi:10.1016/j.chembiol.2013.12.016
Brooijmans, Kuntz, Molecular recognition and docking algorithms, Annual Rev. Biophys. Biomol. Struct
Chauhan, Kalra, Identification of potent COVID-19 main protease (M PRO ) inhibitors from flavonoids, Res. square. Preprint, doi:10.21203/rs.3.rs-34497/v1
Forli, Huey, Pique, Sanner, Goodsell et al., Computational protein-ligand docking and virtual drug screening with the Auto Dock suite, Nat. Protoc, doi:10.1038/nprot.2016.051
Hansdottir, Monick, Vitamin D effects on lung immunity and respiratory diseases, Vitam. Horm
Jin, Du, Xu, Deng, Liu et al., Structure of M pro from SARS-CoV-2 and discovery of its inhibitors, Nature
Joshi, Joshi, Sharma, Mathpal, Pundir et al., In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking, Eur. Rev. Med. Pharmacol. Sci
Jung, Akhmetzhanov, Hayashi, Linton, Yang et al., Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases, J. Clin. Med
Larriba, De Herreros, Muñoz, Vitamin D and the Epithelial to Mesenchymal Transition, Stem Cells Inter, doi:10.1155/2016/6213872
Lybrand, Ligand-protein docking and rational drug design, Curr. Opin. Struct. Biol
Martineau, Jolliffe, Greenberg, Aloia, Bergman et al., Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis, Health Technol. Assess, doi:10.3310/hta23020
Motiwale, Yadav, Kumar, Kushwaha, Choudhir et al., Finding potent inhibitors for COVID-19 main protease (M pro ): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1829501
Narkhede, Pise, Cheke, Cheke, Shinde, Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences, Nat. Prod. Bioprospect, doi:10.1007/s13659-020-00253-1
Pell, Kuang, Viboud, Chowell, Using phenomenological models for forecasting the 2015 Ebola challenge, Epidemics, doi:10.1016/j.epidem.2016.11.002
Rizvi, Shakil, Haneef, A simple click by click protocol to perform docking: Auto Dock 4.2 made easy for nonbioinformaticians, EXCLI J
Roosa, Lee, Kirpich, Rothenberg, Hyman et al., Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24 th, Infect. Disease Mod
Shalayel, Al-Mazaideh, Aladaileh, Fk, Mg, Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2
Shalayel, Al-Qahtani, Huneif, Vitamin D or flu vaccine-benefits over adverse effects, Br. Biomed Bull
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Xu, Baylink, Chen, Reeves, Xiao et al., The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19, J. Transl. Med, doi:10.1186/s12967-020-02488-5
Yang, Xie, Xue, Yang, Ma et al., Design of wide-spectrum inhibitors targeting coronavirus main proteases, PLoS Biol
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors, Science
Zhang, Shen, Yan, Wang, Cheng, Discovery of anti-SARS-CoV-2 agents from commercially available flavor via docking screening, OSF Preprints
{ 'indexed': {'date-parts': [[2024, 4, 11]], 'date-time': '2024-04-11T15:53:24Z', 'timestamp': 1712850804549}, 'reference-count': 0, 'publisher': 'Sciencedomain International', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>In this study, vitamin D has shown greater efficacy of binding with Mpro of COVID-19 ' 'compared to the recently recommended drugs. The docking study was simulated to streamline ' 'interaction effects of Vitamin D, Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and ' 'Azithromycin complexes with the active site of Mpro. Vitamin D is found to have the highest ' 'potential interaction in terms of total H-bond, van der Waal, torsional, and desolvation ' 'energy which were the lowest among all the selected drugs. The hydroxyl group of vitamin D ' 'and the thiol group of Mpro cysteine had played a leading role in increasing Vitamin D ' 'binding and stability with the Mpro pocket by contribution to the inception of three hydrogen ' 'bonds. The study recommend that vitamin D can be added to the COVID-19 treatment protocol, ' 'which may have the desired effect on viral replication inhibition and decreases ' 'mortality.</jats:p>', 'DOI': '10.9734/jpri/2021/v33i29b31603', 'type': 'journal-article', 'created': {'date-parts': [[2021, 5, 29]], 'date-time': '2021-05-29T05:14:19Z', 'timestamp': 1622265259000}, 'page': '186-191', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Vitamin D is a New Promising Inhibitor to the Main Protease (Mpro) of COVID-19 by Molecular ' 'Docking', 'prefix': '10.9734', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-4494-4284', 'authenticated-orcid': False, 'given': 'Ghassab M.', 'family': 'Al-Mazaideh', 'sequence': 'first', 'affiliation': []}, {'given': 'Mohammed H.', 'family': 'Shalayel', 'sequence': 'first', 'affiliation': []}, {'given': 'Farhan K.', 'family': 'Al-Swailmi', 'sequence': 'first', 'affiliation': []}, {'given': 'Saleem H.', 'family': 'Aladaileh', 'sequence': 'first', 'affiliation': []}], 'member': '4694', 'published-online': {'date-parts': [[2021, 5, 26]]}, 'container-title': 'Journal of Pharmaceutical Research International', 'original-title': [], 'link': [ { 'URL': 'https://www.journaljpri.com/index.php/JPRI/article/download/31603/59349', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.journaljpri.com/index.php/JPRI/article/download/31603/59350', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.journaljpri.com/index.php/JPRI/article/download/31603/59349', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 6]], 'date-time': '2022-10-06T11:34:16Z', 'timestamp': 1665056056000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journaljpri.com/index.php/JPRI/article/view/2435'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 5, 26]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.9734/jpri/2021/v33i29B31603', 'relation': {}, 'ISSN': ['2456-9119'], 'subject': [], 'container-title-short': 'JPRI', 'published': {'date-parts': [[2021, 5, 26]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit